{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T20:26:50Z","timestamp":1648585610612},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ygyno.2017.11.032","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T07:30:08Z","timestamp":1512545408000},"page":"363-367","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prophylactic 3-hour graduated infusion schedule minimizes risk of carboplatin hypersensitivity reactions - A prospective study"],"prefix":"10.1016","volume":"148","author":[{"given":"Anjila","family":"Koul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva L.","family":"Forsland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Bjurberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.11.032_bb0005","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0010","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11912-011-0199-3","article-title":"Recurrent ovarian cancer: when and how to treat","volume":"13","author":"Hall","year":"2011","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0015","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1093\/annonc\/mdt406","article-title":"Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data","volume":"24","author":"Raja","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0020","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","article-title":"Clinical features of hypersensitivity reactions to carboplatin","volume":"17","author":"Markman","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2006.10.047","article-title":"Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from women and infants' hospital","volume":"105","author":"Schwartz","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2016.10.023","article-title":"Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin","volume":"144","author":"Bergamini","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0035","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1525-1438.2005.00136.x","article-title":"Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity","volume":"15","author":"Kandel","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2017.11.032_bb0040","doi-asserted-by":"crossref","first-page":"199.e1","DOI":"10.1016\/j.ajog.2007.04.044","article-title":"Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer","volume":"197","author":"Callahan","year":"2007","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/IGC.0000000000000307","article-title":"Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to carboplatin","volume":"25","author":"Kolomeyevskaya","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2017.11.032_bb0050","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2001.19.12.3126","article-title":"Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy","volume":"19","author":"Zanotti","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0055","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1200\/JCO.2003.05.539","article-title":"Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity","volume":"21","author":"Markman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0060","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/IGC.0b013e3181a418ff","article-title":"Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study","volume":"19","author":"Gomez","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2017.11.032_bb0065","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jaci.2011.10.010","article-title":"A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions","volume":"129","author":"Patil","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0070","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0091-6749(96)70134-3","article-title":"A modified, prolonged desensitization protocol in carboplatin allergy","volume":"98","author":"Goldberg","year":"1996","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0075","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0090-8258(03)00178-1","article-title":"Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity","volume":"89","author":"Rose","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00432-003-0501-3","article-title":"Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions","volume":"130","author":"Markman","year":"2004","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0085","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ygyno.2004.08.002","article-title":"Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell\/IgE-mediated reactions","volume":"95","author":"Lee","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0090","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ygyno.2009.10.070","article-title":"The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment","volume":"116","author":"O'Cearbhaill","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0095","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/phar.1769","article-title":"Effect of prophylactic extended-infusion carboplatin on incidence of hypersensitivity reactions in patients with ovarian, fallopian tube, or peritoneal carcinomas","volume":"36","author":"Pasternak","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ygyno.2017.11.032_bb0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jaip.2016.07.010","article-title":"Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer","volume":"5","author":"Lax","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ygyno.2017.11.032_bb0105","first-page":"425","article-title":"Comparison of hypersensitivity reactions to carboplatin retreatment in gynecologic cancer patients between one and two hour infusions: a randomized trial study","volume":"18","author":"Pornwattanakrilert","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0110","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaip.2013.06.002","article-title":"Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy","volume":"1","author":"Caiado","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ygyno.2017.11.032_bb0115","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/cas.12538","article-title":"Carboplatin-induced severe hypersensitivity reaction: role of IgE-dependent basophil activation and FcepsilonRI","volume":"105","author":"Iwamoto","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0120","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ygyno.2006.04.002","article-title":"Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients","volume":"103","author":"Navo","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0125","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1525-1438.2007.01063.x","article-title":"Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer","volume":"18","author":"Gadducci","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2017.11.032_bb0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1517\/14740330903446936","article-title":"Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity","volume":"9","author":"Limsuwan","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0135","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s10147-010-0170-6","article-title":"High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin","volume":"16","author":"Kidera","year":"2011","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0140","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/bjc.2013.389","article-title":"Deleterious BRCA1\/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions","volume":"109","author":"Moon","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.11.032_bb0145","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2011.04.019","article-title":"Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial","volume":"122","author":"Joly","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1006\/gyno.1994.1098","article-title":"Death from anaphylaxis to cisplatin: a case report","volume":"53","author":"Zweizig","year":"1994","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0155","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/gyno.2001.6519","article-title":"Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy","volume":"84","author":"Dizon","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0160","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/CAD.0b013e32833418c0","article-title":"Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?","volume":"21","author":"Syrigou","year":"2010","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ygyno.2017.11.032_bb0165","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jaci.2009.02.042","article-title":"Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management","volume":"123","author":"Hesterberg","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0170","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/cncr.21168","article-title":"Successful carboplatin desensitization in patients with proven carboplatin allergy","volume":"104","author":"Confino-Cohen","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.11.032_bb0175","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2005.06.028","article-title":"Rapid inpatient\/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses","volume":"99","author":"Lee","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0180","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ygyno.2017.11.032_bb0185","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jaip.2015.12.019","article-title":"Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies","volume":"4","author":"Sloane","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ygyno.2017.11.032_bb0190","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ygyno.2016.09.027","article-title":"Platinum desensitization in patients with carboplatin hypersensitivity: a single-institution retrospective study","volume":"144","author":"Altwerger","year":"2017","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817315421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817315421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T12:05:31Z","timestamp":1535198731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817315421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0090825817315421"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.11.032","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylactic 3-hour graduated infusion schedule minimizes risk of carboplatin hypersensitivity reactions - A prospective study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.11.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}